Search

Your search keyword '"Iluvien (Medication)"' showing total 14 results
Start Over Descriptor "Iluvien (Medication)" Journal legal monitor worldwide
14 results on '"Iluvien (Medication)"'

1. Alimera Sciences Announces National Pricing and Reimbursement Granted for ILUVIEN for DME in Belgium

Subjects
Fluocinolone acetonide, Fluocinolone, Disability insurance, Type 2 diabetes, Business, international, Law, Iluvien (Medication)
Abstract

(GlobeNewswire) - Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharmaceuticals, announces that Alimera Sciences Europe Limited, its Ireland-based [...]

Published
2021

3. Alimera Sciences Announces Launch of ILUVIEN in the Netherlands

Subjects
Type 2 diabetes -- Care and treatment, Fluocinolone, Business, international, Law, Iluvien (Medication)
Abstract

(GlobeNewswire) - Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmic pharmaceuticals, announces that Alimera Sciences Europe Limited, its Irish [...]

Published
2020

4. Alimera Sciences Announces Real-World Clinical Data for ILUVIEN to be Presented at the American Academy of Ophthalmology 2020 Virtual Conference

Subjects
Conferences and conventions -- Conferences, meetings and seminars, Ophthalmology -- Conferences, meetings and seminars, Fluocinolone -- Conferences, meetings and seminars, Business, international, Law, American Academy of Ophthalmology -- Conferences, meetings and seminars, Iluvien (Medication)
Abstract

(GlobeNewswire) - Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announces that new real-world [...]

Published
2020

5. Alimera Sciences Obtains Reimbursement Approval for ILUVIEN Use in Non-Infectious Posterior Uveitis in Scotland

Subjects
Clinical trials, Fluocinolone, Uveitis, Business, international, Law, Iluvien (Medication)
Abstract

(GlobeNewswire) - Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmic pharmaceuticals announces that the Scottish Medicines Consortium (SMC), after [...]

Published
2020

6. SMC accepts 14 new medicines for use by NHS Scotland

Subjects
Pertuzumab, Axitinib, Sodium zirconium cyclosilicate, Epilepsy -- Care and treatment, Pembrolizumab, Cannabidiol, Fluocinolone, Business, international, Law, Iluvien (Medication)
Abstract

Fourteen newly licensed medicines have been accepted for use on NHS Scotland by the Scottish Medicines Consortium (SMC), bringing a raft of new treatment options for conditions including epilepsy, depression [...]

Published
2020

7. Alimera Sciences Announces National Reimbursement Granted for ILUVIEN in the Netherlands

Subjects
Type 2 diabetes, Fluocinolone, Business, international, Law, Iluvien (Medication)
Abstract

(GlobeNewswire) - Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmic pharmaceuticals, announces that Alimera Sciences Europe Limited, its Ireland-based [...]

Published
2020

8. Alimera Sciences to Present at the LD Micro 500 Virtual Conference on September 2, 2020

Subjects
Conferences and conventions, Fluocinolone, Business, international, Law, Iluvien (Medication)
Abstract

(GlobeNewswire) - Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmic pharmaceuticals, today announces that Rick Eiswirth, President and Chief [...]

Published
2020

10. Alimera Sciences Appoints Steven T. Gill to the Newly Created Position of Vice President, Thought Leader Engagement

Subjects
Vice presidents (Organizations) -- Appointments, resignations and dismissals, Medical societies, Fluocinolone, Retinal diseases, Ophthalmology, Diseases, Business, international, Law, Iluvien (Medication)
Abstract

(GlobeNewswire) - Alimera Sciences, Inc. (Nasdaq: ALIM), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that it has appointed Steven [...]

Published
2020

12. Alimera Sciences Refinances Its Debt Facility With Solar Capital

Subjects
Syndicated loans, Fluocinolone, Fees, Retinal diseases, Legal fees, Ophthalmology, Company financing, Business, international, Law, Iluvien (Medication)
Abstract

(GlobeNewswire) - Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, today announced that it refinanced [...]

Published
2020

13. EyePoint Pharmaceuticals Announces New Agreement for Expanded Access of DEXYCU Within One of the Largest Integrated Delivery Systems in the U.S

Subjects
Fluocinolone, Distribution channels, Business, international, Law, Dexycu (Medication), Yutiq (Medication), Iluvien (Medication)
Abstract

(GlobeNewswire) - EyePoint Pharmaceuticals, Inc.(NASDAQ: EYPT), a specialty biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that the Company has entered into a formal two-year contract [...]

Published
2019

14. Alimera Announces Regulatory Approval for ILUVIEN in Benelux Countries for The Treatment of Non-Infectious Posterior Uveitis

Subjects
Recurrence (Disease) -- Care and treatment, Fluocinolone, Uveitis -- Care and treatment, Government agencies, Medical supplies, Retinal diseases, Marketing, Ophthalmology, Business, international, Law, Iluvien (Medication)
Abstract

(GlobeNewswire) - Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmology treatments for the management of retinal diseases, announces that the governmental agencies [...]

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results